Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | Addressing financial toxicity and time toxicity among patients with multiple myeloma

Rahul Banerjee • 29 Sep 2023
IMS 2023
Multiple Myeloma Lenalidomide

Rahul Banerjee, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses a study which evaluated financial toxicity and time toxicity in patients with multiple myeloma. Dr Banerjee highlights that financial toxicity was found to be fairly stable among patients, and interestingly, time toxicity was reported in patients on active therapy as well as patients on maintenance therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting/advisory: SparkCures, Sanofi Pasteur, Genentech/Roche, Janssen Oncology, Bristol-Myers Squibb/Celgene, Caribou Biosciences, Pfizer
Research funding: Pack Health

More from Rahul Banerjee

The impact of intensive chemotherapy-based bridging on outcomes of CAR-T therapy in multiple myeloma 3:58
The impact of intensive chemotherapy-based bridging on outcomes of CAR-T therapy in multiple myeloma
Rahul Banerjee • 19 Sep 2025
IVIG prophylaxis should be given for patients with myeloma on bispecifics, regardless of IgG levels 6:22
IVIG prophylaxis should be given for patients with myeloma on bispecifics, regardless of IgG levels
Rahul Banerjee • 19 Sep 2025
Real-world insights into talquetamab dosing patterns for the treatment of myeloma in the U.S. 5:16
Real-world insights into talquetamab dosing patterns for the treatment of myeloma in the U.S.
Rahul Banerjee • 19 Sep 2025
The impact of induction therapy on outcomes for patients with functional high-risk myeloma 4:12
The impact of induction therapy on outcomes for patients with functional high-risk myeloma
Rahul Banerjee • 19 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals